News

Publication of a preclinical study: chronic exposure to SCO-267, a GPR40, is effective in treating diabetes in preclinical models

Publication of a preclinical study: the enteropeptidase inhibitor SCO-792 is therapeutically effective for improving renal function in a nondiabetic rat model of chronic kidney disease

Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, improves obesity via microbiota-driven mechanisms in mice

Conference presentation regarding medicinal chemistry research on a GPR40 full agonist (SCO-267)

Publication regarding medicinal chemistry research on a GPR40 full agonist (SCO-267)

Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, may be a new therapeutic agent for diabetic kidney disease

SCOHIA initiates a phase 1 study on a dual GLP-1 and GIP receptor agonist (SCO-094)

Publication regarding a preclinical study; SCO-267, a GPR40 full agonist, is a novel strategy to treat NAFLD

SCOHIA initiates a phase 2 proof of concept study on an enteropeptidase inhibitor (SCO-792) for diabetic kidney disease

Pipeline Information has been updated.